Aurobindo Pharma reported INR12.77B in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Cipla INR 13.25B 101.8M Dec/2025
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Dr.Reddys Laboratories INR 26.1B 11.63B Jun/2026
Hindustan Unilever INR 16.57B 1.48B Jun/2026
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
UPL INR 15.8B 660M Sep/2025